Technion Research & Development Foundation Limited

Interna Technologies B.v.

Universiteit Maastricht

Academisch Ziekenhuis Maastricht

Pepscan Systems B.v.

Arjan Willem Griffioen

Hubert Van Den Bergh

Roeland Quirinus Jozef Schaapveld

Eugene Berezikov

Willemijn Maria Gommans

Rick Jan Van Haastert

Yehuda G Assaraf

Sanne Weijzen

Andrzej Skladanowski

Petronella Innocentia Van Noort

Patrycja Nowak-Sliwinska

Kristy Gotink

Henk Verheul

Yamit Adar Turgeman

Negar Babae

Edwin Pieter Johan Gerard Cuppen

Meriem Bourajjaj

Wouter Cornelis Puijk

Peter Timmerman

Tilman Mathias Hackeng

Andreas Alphons Franciscus Ludovicus Van Puijenbroek

Andreas Alphons Franciscus Ludovicus Van Piujenbroek

Judith Rosina Van Biejnum

Judith Rosina Van Beijnum

The invention relates to the diagnostic and therapeutic uses of a miRNA molecule, an equivalent or a source thereof in a disease and condition associated with neo-angiogenesis.

MiRNA for treating diseases and conditions associated with neo-angiogenesis

Hydrophobic weak base compounds such as hydrophobic weak base chemotherapeutic agents (which are not an anthracycline) for use in the treatment of medical conditions such as proliferative disease or disorder in a subject, in combination with illumination of a region in a body of the subject which is characterized by the presence of proliferating cells, are disclosed. The hydrophobic weak base compound and a wavelength of illumination are selected such that the hydrophobic weak base compound acts as a therapeutically effective photosensitizer when exposed to the illumination.

Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination

The invention relates to the fields of protein chemistry, biology and medicine. More specifically, it relates to the design and preparation of proteinmimics of members of the cystine-knot growth factor superfamily. Further, the invention relates to the use of these proteinmimics as a medicament or prophylactic agent. The invention provides proteinmimics of members of the cystine-knot growth factor superfamily, preferably for use in immunogenic and/or therapeutic compositions.

Truncated cystine-knot proteins

Growing community of inventors

Heemstede, Netherlands

Arjan Willem Griffioen